Search Result

Results for "

arterial and venous thrombosis

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Factor Xa (4) Isotope-Labeled Compounds (2) Reference Standards (1) Thrombin (7) VKOR (3)
By Research Areas:	Cardiovascular Disease (13)

Inhibitors & Agonists

Peptides

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-122592

Zifaxaban	Factor Xa	Cardiovascular Disease
Zifaxaban is an orally active, competitively and selective Factor Xa (FXa) inhibitor with an IC₅₀ of 11.1 nM for human FXa. Zifaxaban shows >10000-fold greater selectivity than other serine proteases. Zifaxaban can be used for the arterial and venous thrombosis research .

HY-119680

AT-1459	Thrombin	Cardiovascular Disease
AT-1459 is a selective and orally active direct Thrombin inhibitor with a K_i value of 4.9 nM. AT-1459 exhibits excellent antithrombotic activity in both rat models of venous and arterial thrombosis. AT-1459 can be used for research on thrombosis-related diseases .

HY-10270

Flovagatran TGN 255	Thrombin	Cardiovascular Disease
Flovagatran (TGN 255) is a potent and reversible thrombin inhibitor (K_i: 9 nM). Flovagatran can be used in the research of arterial and venous thrombosis .

HY-10271

Flovagatran sodium TGN 255 sodium	Thrombin	Cardiovascular Disease
Flovagatran (TGN 255) sodium is a potent and reversible thrombin inhibitor (K_i: 9 nM). Flovagatran sodium can be used in the research of arterial and venous thrombosis .

HY-14854A

Tecarfarin sodium ATI-5923 sodium	VKOR	Cardiovascular Disease
Tecarfarin (ATI-5923) sodium is an orally active VKOR inhibitor with an IC₅₀ of 0.67 μM against VKORC1. Tecarfarin sodium blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin sodium prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin sodium is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .

HY-19219A

BMS-189664 hydrochloride	Thrombin	Cardiovascular Disease
BMS-189664 hydrochloride is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC₅₀ of 0.046 μM. BMS-189664 hydrochloride can be used for arterial and venous thrombosis research .

HY-19219

BMS-189664	Thrombin	Cardiovascular Disease
BMS-189664 is a potent, selective, and orally active reversible inhibitor of a-thrombin, with an IC₅₀ of 0.046 μM. BMS-189664 can be used for arterial and venous thrombosis research .

HY-14854R

Tecarfarin (Standard) ATI-5923 (Standard)	Reference Standards VKOR	Cardiovascular Disease
Tecarfarin (ATI-5923) (Standard) is the analytical standard of Tecarfarin. This product is intended for research and analytical applications. Tecarfarin is an orally active VKOR inhibitor with an IC₅₀ of 0.67 μM against VKORC1. Tecarfarin blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .

HY-10281

YM-60828 methanesulfonate	Factor Xa	Cardiovascular Disease
YM-60828 methanesulfonate is an orally active, selective and competitive factor Xa inhibitor with a K_i of 1.3 nM and an IC50 of 2.3 nM. YM-60828 methanesulfonate inhibits thrombus formation and platelet aggregation. YM-60828 methanesulfonate can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .

HY-P2021

BMS 180742	Thrombin	Cardiovascular Disease
BMS 180742 is a thrombin exosite inhibitor. BMS 180742 does not inhibit arterial thrombosis .

HY-14854S

Tecarfarin-13C,d3 ATI-5923-¹³C,d₃	Isotope-Labeled Compounds VKOR	Cardiovascular Disease
Tecarfarin- ¹³C,d₃ (ATI-5923- ¹³C,d₃) is ¹³C labeled Tecarfarin. Tecarfarin is an orally active VKOR inhibitor with an IC₅₀ of 0.67 μM against VKORC1. Tecarfarin blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .

HY-164251

RWJ-671818	Thrombin	Cardiovascular Disease
RWJ-671818 is an orally active inhibitor of human α-thrombin with a K_i of 1.3 nM. RWJ-671818 can be studied in research on venous and arterial thrombosis .

HY-10279

YM-60828 hydrochloride	Factor Xa	Cardiovascular Disease
YM-60828 hydrochloride is an orally active, selective and competitive factor Xa inhibitor with a K_i of 1.3 nM and an IC50 of 2.3 nM. YM-60828 hydrochloride inhibits thrombus formation and platelet aggregation. YM-60828 hydrochloride can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .

HY-10280S

YM-60828-d3	Isotope-Labeled Compounds Factor Xa	Others
YM-60828-d₃ is the deuterium labeled YM-60828 (HY-10280). YM-60828 is an orally active, selective and competitive factor Xa inhibitor with a K_i of 1.3 nM and an IC50 of 2.3 nM. YM-60828 inhibits thrombus formation and platelet aggregation. YM-60828 can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .

BMS 180742	Thrombin	Cardiovascular Disease
BMS 180742 is a thrombin exosite inhibitor. BMS 180742 does not inhibit arterial thrombosis .

Cat. No.	Product Name	Chemical Structure

HY-14854S

Tecarfarin-13C,d3
Tecarfarin- ¹³C,d₃ (ATI-5923- ¹³C,d₃) is ¹³C labeled Tecarfarin. Tecarfarin is an orally active VKOR inhibitor with an IC₅₀ of 0.67 μM against VKORC1. Tecarfarin blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .

Tecarfarin-13C,d3

Tecarfarin- ¹³C,d₃ (ATI-5923- ¹³C,d₃) is ¹³C labeled Tecarfarin. Tecarfarin is an orally active VKOR inhibitor with an IC₅₀ of 0.67 μM against VKORC1. Tecarfarin blocks the post-translational modification of vitamin K-dependent coagulation factors II, VII, IX and X, reducing their levels and activities. Tecarfarin prolongs prothrombin time, attenuates venous and arterial thrombosis, increases ear incision bleeding volume, and exerts reversible anticoagulant effects. Tecarfarin is applicable to research related to arterial and venous thrombosis as well as other diseases requiring anticoagulation .

HY-10280S

YM-60828-d3
YM-60828-d₃ is the deuterium labeled YM-60828 (HY-10280). YM-60828 is an orally active, selective and competitive factor Xa inhibitor with a K_i of 1.3 nM and an IC50 of 2.3 nM. YM-60828 inhibits thrombus formation and platelet aggregation. YM-60828 can be used for the research of venous thrombosis, arterial thrombosis, and thromboembolic disorders .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.